Equities Analysts Set Expectations for PCRX Q4 Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Equities researchers at Zacks Research lowered their Q4 2024 earnings estimates for shares of Pacira BioSciences in a research note issued on Wednesday, November 27th. Zacks Research analyst R. Department now anticipates that the company will earn $0.58 per share for the quarter, down from their prior forecast of $0.62. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.26 per share.

Other research analysts also recently issued reports about the company. StockNews.com downgraded Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. Jefferies Financial Group boosted their target price on shares of Pacira BioSciences from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Raymond James downgraded shares of Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research report on Monday, August 12th. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Pacira BioSciences in a research report on Friday, November 8th. Finally, Royal Bank of Canada lifted their price target on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Trading Up 1.6 %

NASDAQ PCRX opened at $16.91 on Monday. The company has a market capitalization of $780.73 million, a price-to-earnings ratio of -8.33 and a beta of 0.82. The company’s 50-day simple moving average is $16.46 and its two-hundred day simple moving average is $19.76. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences has a one year low of $11.16 and a one year high of $35.95.

Institutional Trading of Pacira BioSciences

Several large investors have recently added to or reduced their stakes in PCRX. Pacer Advisors Inc. raised its holdings in shares of Pacira BioSciences by 129.4% during the third quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock worth $74,681,000 after purchasing an additional 2,799,434 shares during the last quarter. Fort Washington Investment Advisors Inc. OH acquired a new position in shares of Pacira BioSciences in the 2nd quarter valued at about $13,240,000. Assenagon Asset Management S.A. boosted its stake in shares of Pacira BioSciences by 314.4% in the third quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock worth $8,324,000 after buying an additional 419,656 shares during the last quarter. Doma Perpetual Capital Management LLC grew its holdings in Pacira BioSciences by 71.8% during the second quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock worth $28,632,000 after acquiring an additional 418,321 shares during the period. Finally, BNP Paribas Financial Markets raised its position in Pacira BioSciences by 269.7% during the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock valued at $5,955,000 after acquiring an additional 288,662 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.